About CorestemChemon
CorestemChemon is a publicly listed company based in Seongnam, South Korea. CorestemChemon is engaged in stem cell therapy and non-clinical research. It operates on a HealthTech and Professional Services model. CorestemChemon offers products and services including Stem Cell Therapy and Non-Clinical CRO Services. Its focus areas include Biotechnology and Stem Cell Therapy.
Company details
CorestemChemon is focused on the development of stem cell therapies and non-clinical CRO services. The company operates in the biopharmaceutical sector, targeting neurological and autoimmune diseases such as ALS, cerebellar ataxia, and lupus through clinical trials and research. Non-clinical research services, including toxicity and efficacy evaluations, are provided for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices. Based in South Korea, the company aims to expand as a global biotech entity through continuous innovation and research collaboration.
- Headquarters Seongnam, South Korea
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website corestemchemon.com
- Legal Name Corestemchemon Inc.
- Annual Revenue$13.96 M (USD)-29.91as on Dec 31, 2025
- Net Profit-$18.58 M (USD)-2.21as on Dec 31, 2025
- EBITDA-$12.55 M (USD)-5.18as on Dec 31, 2025
Products & Services of CorestemChemon
CorestemChemon offers a comprehensive portfolio of products and services, including Stem Cell Therapy and Non-Clinical CRO Services.
Stem cell therapies are developed for neurological diseases.
Non-clinical testing services are provided for toxicity evaluation.
IPO & Listings of CorestemChemon
CorestemChemon is a publicly listed company on the KRX with ticker symbol 166480 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jun 2015
- Listed onKRX: 166480
- Listed entityCORESTEMCHEMON Inc.
- Exchange sectorHealth technology
- ISINKR7166480004
- Share price1,989.00 KRW (-2.5% on the day) · 2026-10-14
- Market capitalisation102,143,562,012.00 KRW
- EPS (diluted, trailing year)-748.64 KRW
- Volume (last session)117,505
Financials of CorestemChemon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 20.16B KRW | -26.83B KRW | -18.13B KRW |
| 2024 | 28.76B KRW | -26.25B KRW | -17.24B KRW |
| 2023 | 33.66B KRW | -17.67B KRW | -15.60B KRW |
| 2022 | 45.88B KRW | -2.26B KRW | -2.05B KRW |
| 2021 | 30.24B KRW | -7.00B KRW | -6.66B KRW |
Detailed financial statements for CorestemChemon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of CorestemChemon
Websites that share an audience with CorestemChemon (corestemchemon.com).
Websites whose visitors overlap most with CorestemChemon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| chemon.co.kr | 37% | 7K | #3,198,221 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CorestemChemon
Annual revenue of CorestemChemon is $13.96M as on Dec 31, 2025.
CorestemChemon is focused on the development of stem cell therapies and non-clinical CRO services. The company operates in the biopharmaceutical sector, targeting neurological and autoimmune diseases such as ALS, cerebellar ataxia, and lupus through clinical trials and research. Non-clinical research services, including toxicity and efficacy evaluations, are provided for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices. Based in South Korea, the company aims to expand as a global biotech entity through continuous innovation and research collaboration.
CorestemChemon offers Stem Cell Therapy and Non-Clinical CRO Services.
Yes, CorestemChemon is publicly traded on KRX under the ticker symbol 166480.